M
Mateusz Kciuk
Researcher at University of Łódź
Publications - 28
Citations - 869
Mateusz Kciuk is an academic researcher from University of Łódź. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 5, co-authored 5 publications receiving 150 citations.
Papers
More filters
Journal ArticleDOI
Mechanisms of Multidrug Resistance in Cancer Chemotherapy.
TL;DR: The aim of this review is to demonstrate the latest data on the mechanisms of cellular resistance to anticancer agents currently used in clinical treatment but also to present the mechanism of action of novel potential antitumor drugs which have been designed to overcome these resistance mechanisms.
Journal ArticleDOI
Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.
TL;DR: A comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity is given and crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38) are outlined.
Journal ArticleDOI
Focus on UV-Induced DNA Damage and Repair—Disease Relevance and Protective Strategies
TL;DR: Current knowledge considering cellular response to UV radiation with special focus on DNA damage and repair is summarized to give a comprehensive insight for new researchers in this field and to highlight most important future prospects considering application of the progressing knowledge of UV response for the clinical control of diverse pathologies.
Journal ArticleDOI
Cyclin-dependent kinases in DNA damage response.
TL;DR: In this article , the role of cyclin-dependent kinase (CDK) in DNA damage response (DDR) has emerged, and the impact of CDKs on DNA repair is discussed.
Journal ArticleDOI
Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies
Mateusz Kciuk,Adrianna Gielecińska,Somdutt Mujwar,Mariusz Mojzych,Beata Marciniak,Rafał Drozda,Renata Kontek +6 more
TL;DR: Current knowledge considering small molecule and antibody-based targeting of CAIX/CAXII in cancer is reviewed, offering an opportunity to develop new targeted therapies with fewer side effects.